Organic Active Ingredients TRIZ Cases

Imidazodiazepine compounds act as positive allosteric modulators on dopamine D1 receptors to enhance therapeutic efficacy.

Lyophilized beta-D-glucan and agarose form a porous matrix that conforms to resection voids, enabling accurate imaging marker visualization.

Compound 1 targets Nav1.8 sodium channels to treat acute and chronic pain while minimizing systemic side effects.

Increasing glutamine concentration to 12-80% of total protein improves cortical, subcortical, and white matter volumes in preterm infants.

Enzymatic hydrolysis and transesterification modify insect-extracted lipids to improve water dispersibility and reduce hardness at lower temperatures.

Segmented radioprotective kits with synergistic formulations provide immediate public access, reducing medical resource burden during radiation emergencies.

Aprotinin carrier protein moves therapeutic agents across the blood-brain barrier via receptor-mediated transcytosis.

A MEK1/2 inhibitor drives neural stem cell differentiation into functional neurons.

A pentaaza macrocyclic ring complex targets specific tumor biomarkers to enable effective cancer treatment.

Dimeric palladium(I) complexes with direct metal-metal bonds overcome hydrolysis instability to treat cisplatin-resistant tumors.

Lung administration of HMW-HA modulates the immune response to prevent cytokine storm, reducing organ damage and mortality in severe COVID-19 cases.

MGL inhibitors elevate endogenous 2-AG levels to provide analgesic effects without synthetic cannabinoid side effects.

Conjugating PMPC to nucleic acid aptamers extends blood half-life and avoids anti-PEG antibody production.

Pyrazolo[1,5-a]pyrimidine compounds treat Pneumovirinae infections by inhibiting viral replication.

Cyclic polyolefin inner layers prevent pharmaceutical sorption while conventional port materials reduce manufacturing costs.

A pharmaceutical composition combining an anti-TFPI antibody with cross-linked hyaluronic acid to inhibit coagulation and protect joint surfaces.

Novel macro-heterocyclic compounds with 17-25 membered rings inhibit hepatitis C virus protease activity.

PRMT5 inhibitors modulate antigen presentation to enhance antitumor immune responses in cancer therapy.

Competitive ALDH3A1 inhibitors prevent drug breakdown, restoring efficacy against resistant cancer cells.

Ester prodrugs of NMDA receptor modulators improve blood-brain barrier permeability to treat depression with reduced psychometric side effects.

Thiomorpholino antisense oligonucleotides induce dystrophin exon skipping with extended serum stability.

Rac1 inhibitors reduce airway hyperresponsiveness and resistance independently of anti-inflammatory effects, addressing severe asthma limitations.

Segmented inhibitor structures reduce pathological neutrophil activity and citrullination levels in rheumatoid arthritis.

Triazolopyridine derivatives resolve nausea and emesis side effects by achieving selective PDE4D inhibition via local quality design.

Segmented cartridges isolate moisture while rigid air conduits deagglomerate diketopiperazine microparticles for consistent dosing.

A nitrogen-containing metal complex achieves high tumor accumulation through specific heterocyclic ring structures.

Administering CD36-expressing fibroblasts shifts metabolism to reduce extracellular matrix accumulation in fibrotic diseases.

Benzopyranyl tetracycle compounds perturb post-translational modification of HMGB proteins to suppress inflammatory responses.

Formula I and II compounds inhibit Galectin-3 activity via beta-galactoside motifs, improving specificity for fibrotic disease treatment.

Tertiary amine piperazine lipids balance uptake and release, overcoming electrostatic binding that hinders intracellular nucleic acid delivery.

Replacing bulky peptidomimetics with compact aminodihydrothiazine scaffolds improves membrane permeability while maintaining inhibition potency.

A dioxane compound acts as a dual TNFR1 antagonist and TNFR2 agonist to modulate renal pathways.

N-butylidenephthalide delays Purkinje cell degeneration by activating adenosine A1 receptors, addressing ineffective treatments for spinocerebellar atrophy.

VE607 binds the spike protein receptor binding domain to block viral entry, reducing escape risk from variants.

Segmenting current across five channels resolves the contradiction between high amplitude requirements and skin safety risks.

Optimized arginine content and nitrogen substitution prevent precipitation and adverse effects in stable dexibuprofen injections.

Formula I compounds block CYP11B2 synthesis, preventing aldosterone breakthrough and organ damage from rebound effects.

Replacing benzyl benzoate with safer solvents improves dissolution rate while maintaining formulation stability.

Naphthyridone compounds inhibit RAF and Bcr-Abl kinases to overcome resistance mechanisms while reducing dose-limiting toxicities.

Native cohumulone in a delayed release capsule activates TAS2R40 receptors to reduce energy intake without causing nausea.

Antisense oligonucleotides bind conserved genomic RNA regions to inhibit viral replication.

Formula Ia compounds act as S1P1 receptor agonists to modulate leukocyte trafficking, resolving bradycardia risks associated with prior agents.

Oral synthetic mescaline administration attenuates substance intake by 20% or more, addressing limited FDA-approved treatments.

Carboxylic acid telmisartan derivatives treat non-alcoholic steatohepatitis by lowering liver triglycerides and fibrosis progression.

Acyl chloride protects the 4-N position of Gemcitabine, preventing metabolic deamination and reducing normal cell cytotoxicity.

Dendrogenin A resolves insufficient immune reprogramming by inducing tumor cell differentiation and enhancing antigen presentation.

Neoadjuvant antibody-drug conjugates overcome therapy resistance in refractory cancers by targeting Trop-2 with SN-38.

Beta-catenin and IDO inhibitors convert non-inflamed tumors into inflamed phenotypes, resolving tumor resistance to checkpoint blockade therapies.